6533b859fe1ef96bd12b8299
RESEARCH PRODUCT
Dupuytren's contracture: an update of biomolecular aspects and therapeutic perspectives.
Francesco MoschellaP NapoliMassimiliano TripoliBartolo CorradinoAdriana Cordovasubject
Pathologymedicine.medical_specialtyGENETIC SUSCEPTIBILITYFIBRONECTINBioinformaticsDISEASEExtracellular matrixTransforming Growth Factor betamedicineFIBROSISHumansGenetic Predisposition to DiseaseDupuytren's contracturePlatelet-Derived Growth FactorTransplantationEpidermal Growth Factorbusiness.industryGROWTH-FACTOR-BETANONOPERATIVE TREATMENTSTEROIDSFibromatosisGranulocyte-Macrophage Colony-Stimulating FactorTissue Inhibitor of MetalloproteinasesFasciaASSOCIATIONmedicine.diseaseHandCOLLAGENFasciotomyFibronectinsbody regionsDupuytren Contracturemedicine.anatomical_structureMetalloproteasesSurgeryContracturemedicine.symptombusinessPalmar fasciaMyofibroblastMATRIXPalmar Fibromatosisdescription
The so-called fibrogenic cytokines, able to induce the growth of fibroblasts and their differentiation into myofibroblasts and to stimulate their production of extracellular matrix, are involved in the genesis of Dupuytren’s contracture. Although many studies have been made of biomolecular aspects of palmar fibromatosis, practical applications from them are still far from imminent because of the real difficulty of blocking their action in vivo, even in a chronic, progressive lesion such as Dupuytren’s disease. Consequently, surgical excision of the palmar fascia still remains the treatment of choice.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2005-12-01 | Journal of hand surgery (Edinburgh, Scotland) |